Stay updated with breaking news from Refactor Health. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),
NEW HAVEN, Conn., October 12, 2023--BioCT is delighted to announce the appointment of David Scheer as Co-Chair of its Board of Directors. With a distinguished career in the life sciences industry and extensive experience in building successful companies, David brings invaluable expertise to his new leadership role within BioCT.
GUILFORD, Conn., July 12, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment of David Scheer as Chairman
Stanford researchers lay out a framework for engineers as they expand and build new medical artificial intelligence models.